Update on the angiotensin AT2 receptor

Current Hypertension Reports

Volumn 15, Issue 1, 2013, Pages 25-30

  McCarthy, Claudia A ^a   Widdop, Robert E ^a   Denton, Kate M ^a   Jones, Emma S ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Ang peptides; Angiotensin II; Angiotensin III; Angiotensin peptides; Antifibrotic; AT2 receptor; AT2R; AT2R agonists; Beta substituted amino acids; Blood pressure; Brain function; C21; Compound 21; Hypertension; Kidney; Neuroprotection; Organ protection; Vascular

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR AGONIST; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN III; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-9]; ANTIHYPERTENSIVE AGENT; C 21; CARDIOVASCULAR AGENT; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; PD 1233119; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BRAIN FUNCTION; BRAIN INFARCTION; BRAIN PROTECTION; DRUG EFFICACY; DRUG RECEPTOR BINDING; GENDER; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NATRIURESIS; NONHUMAN; PROTEIN FUNCTION; RECEPTOR AFFINITY; RENAL PROTECTION; REVIEW; VASODILATATION;

ANGIOTENSIN III; ANIMALS; HUMANS; KIDNEY; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; RECEPTOR, ANGIOTENSIN, TYPE 2;

EID: 84872610780     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0321-4     Document Type: Review

References (59)

1. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 2003;12:70-88. (Pubitemid 36700689)
2. Widdop RE, Jones ES, Hannan RE, et al. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol. 2003;140:809-24. (Pubitemid 37464062)
3. Henrion D, Kubis N, Levy BI. Physiological and pathophysiological functions of the AT(2) subtype receptor of angiotensin II: from large arteries to the microcirculation. Hypertension. 2001;38:1150-7. (Pubitemid 34252821)
4. Wharton J, Morgan K, Rutherford RA, et al. Differential distribution of angiotensin AT2 receptors in the normal and failing human heart. J Pharmacol Exp Ther. 1998;284:323-36. (Pubitemid 28109563)
5. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res. 1998;83:1182-91. (Pubitemid 29006033)
6. Jones ES, Vinh A, McCarthy CA, et al. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther. 2008;120:292-316.
7. Hein L, Meinel L, Pratt RE, et al. Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol. 1997;11:1266-77. (Pubitemid 28041334)
8. Widdop RE, Matrougui K, Levy BI, et al. AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension. 2002;40:516-20.
9. Stoll M, Steckelings UM, Paul M, et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651-7.
10. Porrello E, Delbridge L, Thomas W. The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front Biosci. 2009;14:958-72.
11. Verdonk K, Danser AH, van Esch JH. Angiotensin II type 2 receptor agonists: where should they be applied? Expert Opin Investig Drugs. 2012;21:501-13.
12. Whitebread S, Mele M, Kamber B, et al. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun. 1989;163:284-91. (Pubitemid 19227303)
13. Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995-6008. (Pubitemid 39507341)
14. Kaschina E, Grzesiak A, Li J, et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation. 2008;118:2523-32.
15. 2 receptor stimulation with antiinflammatory effects.
16. Li XC, Widdop RE. AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR. Br J Pharmacol. 2004;142:821-30. (Pubitemid 38998096)
17. Barber MN, Sampey DB, Widdop RE. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension. 1999;34:1112-6.
18. •• Bosnyak S, Welungoda IK, Hallberg A, et al. Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol. 2010;159:709-16. Comprehensive dose-ranging study of the in vitro and in vivo vascular effects of Compound 21.
19. 2 receptors.
20. Moltzer E, Verkuil AV, van Veghel R, et al. Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation. Hypertension. 2010;55:516-22.
21. Henrion D. Why do we need a selective angiotensin II type 2 receptor agonist? Hypertension. 2012;60:616-7.
22. Regoli D, Park WK, Rioux F. Pharmacology of angiotensin. Pharmacol Rev. 1974;26:69-123.
23. de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-72.
24. 1 receptor selectivity.
25. Padia SH, Kemp BA, Howell NL, et al. Conversion of Renal Angiotensin II to Angiotensin III Is Critical for AT2 Receptor Mediated Natriuresis In Rats. Hypertension. 2008;51:460-5. (Pubitemid 351156433)
26. Padia SH, Kemp BA, Howell NL, et al. Intrarenal Aminopeptidase N Inhibition Augments Natriuretic Responses to Angiotensin III in Angiotensin Type 1 Receptor-Blocked Rats. Hypertension. 2007;49:625-30.
27. Padia SH, Howell NL, Siragy HM, et al. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension. 2006;47:537-44. (Pubitemid 43843872)
28. Walters PE, Gaspari TA, Widdop RE. Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension. 2005;45:960-6. (Pubitemid 40628944)
29. Vinh A, Widdop RE, Drummond GR, et al. Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res. 2008;77:178-87. (Pubitemid 351195149)
30. • Bosnyak S, Widdop RE, Denton KM, et al. Differential mechanisms of Ang (1-7)-mediated vasodepressor effect in adult and aged candesartan-treated rats. Int J Hypertens. 2012;2012:192567. Striking difference in the vascular phenotype of Ang (1-7) given acutely to either young-adult or aged conscious rats.
31. Rosenstrom U, Skold C, Lindeberg G, et al. A selective AT2 receptor ligand with a gamma-turn-like mimetic replacing the amino acid residues 4-5 of angiotensin II. J Med Chem. 2004;47:859-70. (Pubitemid 38176789)
32. Johannesson P, Erdelyi M, Lindeberg G, et al. AT2-selective angiotensin II analogues containing tyrosine-functionalized 5,5-bicyclic thiazabicycloalkane dipeptide mimetics. J Med Chem. 2004;47:6009-19. (Pubitemid 39507342)
33. 2 receptor antagonist by minor substitutions to the structure of Compound 21.
34. 1 receptor selectivity and function.
35. Ocaranza MP, Lavandero S, Jalil JE, et al. Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro. J Hypertens. 2010;28:1054-64.
36. Flores-Munoz M, Smith NJ, Haggerty C, et al. Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. J Physiol. 2011;589:939-51.
37. 2 receptors, although a contribution by other metabolized Ang peptides and mechanisms needs to be fully ruled out.
38. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1-9.
39. Padia SH, Kemp BA, Howell NL, et al. Mechanisms of dopamine D(1) and angiotensin type 2 receptor interaction in natriuresis. Hypertension. 2012;59:437-45.
40. Salomone LJ, Howell NL, McGrath HE, et al. Intrarenal dopamine D1-like receptor stimulation induces natriuresis via an angiotensin type-2 receptor mechanism. Hypertension. 2007;49:155-61. (Pubitemid 46360355)
41. •• Kemp BA, Bell JF, Rottkamp DM, et al. Intrarenal angiotensin III is the predominant agonist for proximal tubule angiotensin type 2 receptors. Hypertension. 2012;60:387-95. Current paper from a series of publications that shows Ang III, but not Ang II or Ang (1-7), causes AT2 receptor mediated natriuresis.
42. Brown RD, Hilliard LM, Head GA, et al. Sex Differences in the Pressor and Tubuloglomerular Feedback Response to Angiotensin II. Hypertension. 2012;59:129-35.
43. Sampson AK, Moritz KM, Jones ES, et al. Enhanced angiotensin II type 2 receptor mechanisms mediate decreases in arterial pressure attributable to chronic low-dose angiotensin II in female rats. Hypertension. 2008;52:666-71.
44. 2 receptors in renal vasculature in female, as compared to male, rats.
45. 2 receptor-mediated renal vasodilator response to Compound 21 in female, as compared to male, rats.
46. 2 receptor antagonist PD123319 was not examined.
47. 2 receptor antagonist PD123319 was not examined.
48. • Matavelli LC, Huang J, Siragy HM. Angiotensin AT2 Receptor Stimulation Inhibits Early Renal Inflammation in Renovascular Hypertension. Hypertension. 2011;57:308-13. One of the first studies to show anti-inflammatory effects of Compound 21 in the kidney after short-term treatment with Compound 21.
49. Gelosa P, Pignieri A, Fändriks L, et al. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens. 2009;27:2444-51.
50. Foulquier S, Steckelings UM, Unger T. Impact of the AT(2) receptor agonist C21 on blood pressure and beyond. Curr Hypertens Rep. 2012;14:403-9.
51. Jehle AB, Xu Y, Dimaria JM, et al. A nonpeptide angiotensin II type 2 receptor agonist does not attenuate postmyocardial infarction left ventricular remodeling in mice. J Cardiovasc Pharmacol. 2012;59:363-8.
52. McCarthy CA, Vinh A, Callaway JK, et al. Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke. Stroke. 2009;40:1482-9.
53. •• McCarthy CA, Vinh A, Broughton BR, et al. Angiotensin II Type 2 Receptor Stimulation Initiated After Stroke Causes Neuroprotection in Conscious Rats. Hypertension. 2012, Oct 22 [Epub ahead of print]. Proof-of-principle report showing that CGP42112, given centrally 6 hours after stroke in conscious spontaneously hypertensive rats, still evoked neuroprotection.
54. •• Lee S, Brait V, Arumugam T, et al. Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo. Exp Transl Stroke Med. 2012, 4: Aug 24 [Epub ahead of print]. Proof-of-principle report showing that CGP42112, given peripherally at the time of ischaemia/reperfusion in anaesthetised mice, evoked neuroprotection.
55. Shraim N, Mertens B, Clinckers R, et al. Microbore liquid chromatography with UV detection to study the in vivo passage of compound 21, a non-peptidergic AT2 receptor agonist, to the striatum in rats. J Neurosci Methods. 2011;202:137-42.
56. • Mecca AP, Regenhardt RW, O'Connor TE, et al. Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp Physiol. 2011;96:1084-96. First report showing that Ang (1-7) can also evoke neuroprotective effects.
57. Tota S, Hanif K, Kamat PK, et al. Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function. Psychopharmacology (Berl). 2012;222:185-202.
58. •• Jing F, Mogi M, Sakata A, et al. Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. J Cereb Blood Flow Metab. 2012;32:248-55. First report on the improved cognitive effects of Compound 21.
59. • Horiuchi M, Iwanami J, Mogi M. Regulation of angiotensin II receptors beyond the classical pathway. Clin Sci. 2012;123:193-203. An excellent recent review summarising a number of aspects of nonclassical Ang signaling that are not covered in the current update.